The Latest Cardiac and Vascular News
2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion – $1.259 billion, up approximately 9.0% – 9.4% year-over-year 2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% – 9.9% year over year 2023 financial results and 2024 guidance to be released February 28, […]
ALISO VIEJO, Calif., Jan. 8, 2024 /PRNewswire/ — Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced the appointment of Rhonda Robb as President and Chief…
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million […]
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2024, which ended November 30, 2023. “Today, we are announcing meaningful steps in our strategic transformation. We have initiated a restructuring of our
SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, at […]
HUNTINGTON BEACH, Calif. & HOUSTON & GOLD COAST, Australia–(BUSINESS WIRE)–BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors. “We are thrilled to have him join as CEO.” […]
$6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif., Jan. 3, 2024 /PRNewswire/ — Vasa Therapeutics, Inc. (“Vasa”), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the…
MINNEAPOLIS, Jan. 2, 2024 /PRNewswire/ — Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced it has closed on $13M in fresh capital ($42M to-date). CardioMech received strong financial support from existing and new investors, including a non-disclosed strategic investor. The heavily oversubscribed round […]
BRAINTREE, Mass., Jan. 2, 2024 /PRNewswire/ — In a significant move to enhance their impact on global cardiac care, PrepMD and its subsidiaries, including PrepMD RMS, have unified under a single brand name and logo: ‘PrepMD’. This strategic decision marks a key milestone in their ongoing…
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA), 0440U, for the company’s AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. Receipt of this new CPT […]
